Varicella-Zoster Virus (VZV) Diagnostic Market: By Drug Type (Acyclovir, Valacyclovir, Famciclovir, and Others), By Based on the Route of Administration (Oral, Injectable, and Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-commerce), and Geography

Varicella-Zoster Virus (VZV) Diagnostic Market held a significant market share during the forecast period. Preventing varicella zoster infection through vaccination strategies avoids the primary infections in neonates and vulnerable cases. The increasing risk of postnatal varicella zoster infection in children less than 1 year of age will use acyclovir as the first line of treatment for these infected children will drive the growth of the market in the future. The increasing incidences of viral-borne disease among children and the old population, high transmission rate of the infection, high occurrence of infections in low or middle-income countries, and growing revenue of the market players are the major factors contributing to the growth of the varicella-zoster infection treatment market.

Moreover, the companies are focusing on organic and inorganic growth by introducing their products and gaining maximum market share.  In addition, acquisitions, expansion of product portfolio, and research & development capabilities are predicted to create opportunities for the growth of the market. However, to ensure safety and accuracy, the development and commercialization of viral antigen diagnostic tests must stick to strict regulatory requirements. There may be a significant barrier for both established companies and start-ups in the global viral antigen diagnostics market to comply with the regulations and quality control standards.

Varicella-Zoster Virus (VZV) Diagnostic Market Key Developments:

• In July 2021, US Food and Drug Administration (FDA) authorized posoleucel (Viralym-M, ALVR105) as an orphan drug designation (ODD) for the treatment of hemorrhagic cystitis (HC) which is caused by viruses.
• In April 2017, U.S. FDA approved the Mylan pharmaceuticals which is the subsidiary of Mylan Inc for acyclovir ointment USP, the zovirax ointment is the first generic version of Valeant International.
• In December 2016, The slayback made an agreement with Sandoz for the sale and marketing rights of slayback Generic Zovirax Ointment (Acyclovir Ointment) due to which the Novartis position augmented in the market by getting the rights of sales and marketing.
• In Dec 2015, valeant pharmaceuticals, Inc. agreed with walgreens which helped the company foray into the pharmaceutical retail business.